Sep 6, 2022 9:00 am EDT Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 8:28 am EDT Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Aug 12, 2022 7:00 am EDT Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
Aug 8, 2022 7:00 am EDT Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Aug 3, 2022 8:00 am EDT Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
Jul 7, 2022 8:00 am EDT Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
Jun 29, 2022 9:00 am EDT Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Jun 21, 2022 7:30 am EDT Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer